|
Characteristics
| |
RMSTb (95%CI)
|
HRc (95%CI)
|
P valuea
|
Interaction p
|
|---|
|
Non- Chemotherapy
|
Chemotherapy
|
|---|
|
Total
|
–
|
53.3 (50.9–55.2)
|
56.0 (54.0–57.4)
|
0.584 (0.333–1.025)
|
0.058
|
–
|
|
Sex
|
Male
|
52.0 (48.1–54.6)
|
55.9 (53.2–57.6)
|
0.487 (0.240–0.991)
|
0.042
|
0.157
|
|
Female
|
55.0 (50.7–57.2)
|
56.1 (52.8–58.0)
|
0.787 (0.310–2.003)
|
0.615
| |
|
Age (years)
|
≤55
|
53.8 (46.6–57.2)
|
56.6 (50.7–59.0)
|
0.536 (0.128–2.251)
|
0.386
|
0.574
|
|
56–60
|
54.6 (45.6–58.2)
|
57.1 (48.8–59.2)
|
0.584 (0.097–3.499)
|
0.551
| |
|
61–65
|
53.2 (45.7–57.0)
|
55.6 (49.8–58.3)
|
0.641 (0.171–2.403)
|
0.505
| |
|
66–70
|
54.2 (47.2–57.3)
|
57.5 (52.6–59.1)
|
0.392 (0.098–1.576)
|
0.170
| |
|
> 70
|
52.0 (46.9–55.2)
|
53.9 (49.1–56.9)
|
0.748 (0.305–1.830)
|
0.522
| |
|
Location
|
Rectum
|
52.4 (48.6–55.0)
|
54.6 (51.2–56.8)
|
0.725 (0.366–1.435)
|
0.353
|
0.283
|
|
Colon
|
54.5 (50.6–56.9)
|
57.5 (54.9–58.9)
|
0.428 (0.158–1.163)
|
0.086
| |
|
Size (cm)
|
≤5.0
|
54.3 (50.8–56.6)
|
56.7 (54.0–58.1)
|
0.548 (0.236–1.269)
|
0.153
|
0.165
|
|
> 5.0
|
52.6 (48.6–55.4)
|
55.1 (51.8–57.3)
|
0.672 (0.312–1.449)
|
0.307
| |
|
Differentiation
|
Well-moderate
|
53.5 (50.8–55.4)
|
56.1 (54.0–57.5)
|
0.570 (0.315–1.031)
|
0.059
|
0.702
|
|
Poor
|
50.5 (36.8–56.9)
|
53.8 (39.9–58.2)
|
0.711 (0.117–4.339)
|
0.708
| |
|
T category
|
3
|
58.1 (54.7–59.3)
|
57.3 (54.2–58.9)
|
1.439 (0.342–6.045)
|
0.618
|
0.072
|
|
4
|
50.9 (47.1–53.4)
|
55.2 (52.1–57.0)
|
0.501 (0.267–0.939)
|
0.027
| |
|
CEAd (ng/mL)
|
< 5
|
55.2 (51.8–57.1)
|
57.3 (54.4–58.7)
|
0.557 (0.219–1.414)
|
0.211
|
0.790
|
|
≥5
|
52.4 (46.8–55.7)
|
55.0 (51.0–57.4)
|
0.641 (0.265–1.552)
|
0.320
| |
|
Examined lymph nodes
|
< 12
|
50.7 (44.5–54.8)
|
51.7 (46.5–55.1)
|
0.898 (0.381–2.118)
|
0.806
|
0.322
|
|
≥12
|
54.1 (51.4–56.0)
|
57.5 (55.5–58.7)
|
0.404 (0.185–0.882)
|
0.018
| |
|
PLRe
|
≤130
|
55.3 (51.8–57.4)
|
54.9 (52.0–56.8)
|
1.080 (0.495–2.355)
|
0.847
|
0.038
|
|
> 130
|
51.3 (47.2–54.2)
|
57.6 (54.2–59.0)
|
0.272 (0.102–0.726)
|
0.005
| |
- a P value of the log-rank test
- b RMST: the restricted mean survival time
- c HR: Hazard Ratio, chemotherapy patients vs. non-chemotherapy patients
- d CEA: carcinoembryonic antigen
- e PLR: platelet to lymphocyte ratio
